FUTURE OF HEALTHCARE

Lionel Richie Partners With All-In-One Healthcare Company, Devoted Health

Devoted Health | October 04, 2022 | Read time : 02:00 min

Lionel Richie

The iconic singer, actor, and American Idol judge, Lionel Richie is partnering with Devoted Health, a new kind of healthcare company providing all-in-one care for Americans on Medicare.

Richie has long been dedicated to improving healthcare access, and through this partnership, he will support Devoted Health’s expanding efforts to offer higher-quality care to more Americans on Medicare across the country.

“Getting great healthcare needs to be a lot easier for folks. Devoted is making this happen by bringing all of the ingredients for quality healthcare together.” Richie said. “Devoted cares for each member with all-in-one healthcare. Better quality healthcare from better coordination of care can really make a difference to folks who want to live their best and most fulfilling lives. I am excited to partner with Devoted to change and improve healthcare in America!”

Devoted Health is changing healthcare for the better through its innovative all-in-one healthcare solution, which combines Devoted Health Medicare Advantage plans, access to top local providers alongside specialized care delivered by Devoted Medical, full-service guides for more personalized coordination, and world-class technology that powers it all. The result of bringing these exceptional ingredients together into one seamless offering is a complete, coordinated, and customized healthcare experience for each Devoted member.

"We are thrilled to work with Lionel Richie, who is such an inspiring leader and so deeply passionate about making healthcare easier for everyone. We couldn't imagine a better spokesperson and ally than Lionel Richie."

Todd Park, Executive Chairman of Devoted Health

About Devoted Health
Devoted Health is an all-in-one healthcare company on a mission to dramatically improve the health and well-being of older Americans by caring for every person like family. To accomplish this, Devoted Health has designed and built an integrated healthcare solution that combines Devoted Health Medicare Advantage plans, access to top local providers alongside virtual and in-home care delivered by Devoted Medical, full-service guides, and world-class technology that powers it all. The result of bringing all of these exceptional ingredients into one seamless offering is a complete, coordinated, and customized healthcare experience for each Devoted member. Founded in 2017 by brothers Todd and Ed Park, Devoted now serves over 70,000 members across Florida, Texas, Arizona, Ohio, and Illinois. 
 

Spotlight

This video displays the Clinical Education programme from GE Healthcare. It is aimed at all the users of medical imaging equipment, as well as hospital decision makers.

Spotlight

This video displays the Clinical Education programme from GE Healthcare. It is aimed at all the users of medical imaging equipment, as well as hospital decision makers.

Related News

FUTURE OF HEALTHCARE

Medcase & NTT DATA Sign a Definitive Agreement to Enable Healthcare AI Developers a Holistic Solution to Access, Annotate

Medcase | November 29, 2022

Medcase, a leading solution provider for healthcare AI, and NTT DATA, a digital business and IT services leader, have signed a definitive agreement to enable data discovery and enrichment solutions for healthcare imaging. AI in healthcare is beginning to demonstrate an ability to improve productivity and outcomes in a competitive market space. Fulfilling data needs and enriching image data sets with annotation and labeling confronts an industry focused on critical development and release timelines. The new partnership between Medcase and NTT DATA addresses that inefficiency allowing AI developers and life sciences to focus on their training and data science. “Enabling access to rich medical datasets has become paramount to our customers focused on reducing the time from concept to algorithm production. Partnering with NTT DATA is exciting for us as we can now assist innovators with access to curated data, coupled with our enrichment solutions powered by Medcase’s global network of health care professionals and annotators from radiologists to gastroenterologists working side by side with AI developers.” Kyle Giddens, CEO and Co-Founder of Medcase The collaboration will enable innovators working with Medcase to access enriched patient studies, including medical imaging, through NTT DATA’s Advocate AI data cooperative network. Medcase’s curation services and AI annotation solutions leverage a global network of healthcare experts to identify, diagnose, and audit medical data according to annotation and labeling guidelines from research, all the way to FDA reader studies. “Data diversity across technology and patient populations is fundamental to ensuring strong analytics’ training and high conformance,” said Mitchell Goldburgh, Senior Director, Enterprise Imaging and Analytics, NTT DATA Services. “Confidence in AI grows by having a dynamic and broadly trained team of annotators complementing the data with their diversity in the art of annotation. We are pleased to have been chosen by Medcase as a go-to-market partner in advocating the adoption of AI.” “Advancing technology innovation in the digital and medical space is the best way to improve patient outcomes quickly,” said Giddens. “This is why we are excited to partner with NTT DATA to accelerate AI to the market with essential data annotation, labeling, and enablement that they need to innovate. Access to health care professionals should be as easy as spinning up a new cloud instance on Amazon, we make that easy with our platform and API’s.” About NTT DATA NTT DATA is a $30 billion trusted global innovator of IT and business services. We help clients transform through business and technology consulting, industry and digital solutions, applications development, and managed edge-to-cloud infrastructure services, BPO, systems integration, and global data centers. We are committed to our client's long-term success and combine global reach with local client service in over 80 countries. About Medcase Medcase is changing how businesses access medical expertise, knowledge, and data by building the largest global network of on-demand healthcare professionals working remotely to assist healthcare innovators and AI developers. By empowering leading industry leaders in medical devices, AI, and technology companies to pharmaceuticals and telemedicine, Medcase helps accelerate healthcare innovation and bring new medical technologies to market by connecting them to experts to enrich medical data, surveys, or interviews to assess go-to-market and regulation and even providing staffing for valuable telehealth or remote patient monitoring services.

Read More

HEALTH TECHNOLOGY

Inbound Health Launches to Enable Partners to Build and Scale Hospital and Skilled Nursing Facility-at-Home Care Models

Allina Health and Flare Capital Partners | October 19, 2022

Allina Health and Flare Capital Partners announced the launch of Inbound Health, a new company that enables health systems and health plans to offer hospital-at-home and skilled nursing-at-home programs. These innovative new care models create the ability to care for patients requiring facility-level acute or post-acute care in their home, thereby improving patient access, satisfaction, and outcomes while lowering total cost of care. Inbound Health provides the full stack of capabilities that are required to scale at-home care models including home-based care pathways, virtual care teams, engagement and workflow technology, analytics, supply chain partnerships, operational oversight and payment models. The company's flexible partnership structure enables customers to leverage their existing assets and capabilities while relying on Inbound Health to fill the gaps required to scale these programs across their service area To date, more than 4,200 patients across 185 primary diagnoses have been cared for through the Inbound Health platform, which has been operational in Allina Health’s service area since May 2020. The program has allowed Allina Health to manage a wider swath of the continuum of care for its patients, thereby ensuring that care is delivered in a safe, coordinated and patient-centric manner. The company combines biometric monitoring, digital surveillance, in-home nursing and therapy, virtual visits with hospitalists and geriatricians, and a comprehensive supply chain to deliver a safe and high-quality care program. Inbound Health has proven that the program lowers total-cost-of-care by 30-40% on a risk-adjusted basis while achieving similar or improved clinical outcomes when compared to traditional facility-based care. These outcomes have enabled Inbound Health and Allina to develop unique episodic-based payer contracts with multiple Commercial and Medicare Advantage payers in Minnesota, a payment model that the company plans on replicating with partners in other markets. “The home hospital programs that we’ve scaled to thousands of patients here in Minnesota are rooted in our Population Health drivers of delivering safe, high quality, affordable care that’s timely and convenient to access. We are excited for Inbound Health to leverage the capabilities and know-how that power these programs to scale similar at-home programs across the nation.” Lisa Shannon, President and CEO of Allina Health Inbound Health will be led by CEO Dave Kerwar who brings a 20-year track record of executing leading-edge strategies to improve care quality, reduce cost, and create consumer-centricity in healthcare. Previously, Dave was the Chief Product Officer at Mount Sinai Health System where he built innovative technology-enabled operations to scale direct-to-consumer, direct-to-employer, and population health programs. Prior to Mount Sinai, Dave led business development for Aetna’s Joint Ventures where he launched Provider Owned Health Plans with leading health systems across the country. “We are proud to be backed by one of the most prestigious health systems and one of the largest dedicated healthcare technology venture capital firms in the country in our pursuit to revolutionize this new level of care,” said Dave Kerwar. “Inbound Health will leverage the clinical, operational, and technology assets that we’ve developed alongside Allina Health to enable our customers nationwide to safely offer facility-level care in the home, at a lower cost and with an elevated patient and caregiver experience.” Inbound Health will use the new financing to continue to advance its proprietary technology platform that integrates with a variety of biometric monitoring devices and brings forward engagement, workflow, and AI-powered analytic capabilities that are purpose-built to scale these at-home care programs. This platform optimizes Inbound Health’s ability to perform key functions on behalf of its partners, including: “Home-based acute care models represent a compelling opportunity to lower the cost of care while increasing access and satisfaction for patients,” said Michael Greeley, Co-founder and General Partner, Flare Capital Partners. “Inbound Health is truly differentiated, not only due to the unique clinical and technology assets that underpin the platform, but also because it has powered one of the largest hospitals and SNF-at-home programs in the country. We look forward to partnering with Dave and the Inbound Health team to scale this platform nationally.” About Allina Health Allina Health is dedicated to the prevention and treatment of illness and enhancing the greater health of individuals, families and communities throughout Minnesota and western Wisconsin. A not-for-profit health care system, Allina Health cares for patients from beginning to end-of-life through its 90+ clinics, 12 hospitals, 14 retail pharmacies, specialty care centers and specialty medical services that provide home care, senior transitions, hospice care, home oxygen and medical equipment, and emergency medical transportation services. About Flare Capital Partners Flare Capital Partners strives to help build significant healthcare technology, digital health, and healthcare services companies to improve health outcomes and broaden access while lowering costs of care. We partner with inspirational entrepreneurs who seek to transform the business of healthcare by developing innovative and impactful products and services. Flare Capital is a team of proven healthcare technology investors and senior operating executives known for thought leadership and unparalleled strategic industry resources. Our firm has raised some of the industry’s largest dedicated venture capital funds focused on early-stage opportunities in healthcare technology innovation, and our investors include leading healthcare companies, major institutional investors, important family offices, foundations, and sovereign wealth funds. We are full life-cycle investors in our portfolio companies as we work alongside entrepreneurs over their entire company-building journey. Select portfolio companies include Aetion, Aspen RxHealth, Bright Heath, Cayaba Care, Cohere Health, Eden Health, HealthVerity, Inbound Health, Iora Health, Oshi Health, Somatus, and VisitPay. The firm has developed the very successful Flare Scholar program with over 250 participants and actively leverages its extended industry network, Executive Partners, and Industry Advisory Board for the benefit of the entrepreneurs and founders with whom it is privileged to partner.

Read More

HEALTH TECHNOLOGY

Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trial

Novartis Pharma AG | September 19, 2022

Sandoz, a global leader in off-patent medicines, announces further progress on its biosimilar pipeline, with the release of positive results from the integrated ROSALIA Phase I/III clinical trial study for its proposed biosimilar denosumab. “Biosimilars have the opportunity to create a substantial positive impact on patient access and healthcare systems sustainability. Therefore, this important milestone means that we are one step closer to giving individuals living with osteoporosis access to a more affordable, biosimilar version of this critical medicine, which may help to change the course of their disease.” Florian Bieber, Global Head of Development, Sandoz Biopharmaceuticals Denosumab is indicated for treating a variety of conditions, including osteoporosis in postmenopausal women, in men at increased risk of fractures, treatment-induced bone loss, prevention of skeletal related complications in cancer that has spread to the bone, and giant cell tumor of the bone2,3,4,5. The results from the integrated Phase I/III study confirm the biosimilar matches the reference medicine in terms of pharmacokinetics, pharmacodynamics, efficacy, safety and immunogenicity in the respective indications; and contributes to demonstration of similarity, which is the basis for use in all indications. Approximately 500 million men and women worldwide may be affected by osteoporosis1, which causes 8.9 million fractures annually – or one fracture every three seconds1. By 2050, hip fractures are projected to increase by 240% in women and 310% in men compared to 19901. The results come soon after Sandoz confirmed acceptance of license applications for two other proposed biosimilars. In July 2022, the application for the first-of-a-kind multiple sclerosis proposed biosimilar natalizumab was accepted for review by the US Food and Drug Administration (FDA) and European Medicines Agency. In June 2022, the EMA and FDA accepted for review Sandoz applications for the high-concentration formulation 100 mg/mL (HCF) of its biosimilar adalimumab. Sandoz biosimilars help patients, in areas including immunology, oncology, nephrology, supportive care and endocrinology, access critical and potentially life-changing medicines sustainably and affordably. Sandoz has a leading global portfolio with eight marketed biosimilars and a further 15-plus in various stages of development. About ROSALIA6 In ROSALIA, 527 postmenopausal women with osteoporosis were randomized to receive either biosimilar denosumab or the reference medicine for up to 78 weeks of treatment. Objectives were to demonstrate similar efficacy in terms of change in lumbar spine bone mineral density, as well as similar pharmacokinetics and pharmacodynamics. The global clinical program for biosimilar denosumab was developed in consultation with major regulatory agencies and the results from this clinical study are expected to support regulatory approval. About denosumab Denosumab is a human monoclonal antibody designed to bind to the RANKL protein, an activator of osteoclasts (cells involved in breaking down bone tissue)2. By binding to and inhibiting RANKL, denosumab decreases the production and activity of osteoclasts, resulting in a reduction of bone loss, and subsequently the likelihood of fractures and other serious bone conditions2.

Read More